Primary results of TITRATE-HF: 1-year continuous GRMT implementation, prognosis, and LVEF improvement in de novo heart failure with reduced ejection fraction

17 May 2025 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Professor Jasper Brugts

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail

Discussant panel

Presentation thumbnail

Sudden cardiac arrest in patients with newly diagnosed NICM or MI/CAD - nationwide analysis of >19.000 patients with a WCD

Professor J. Bauersachs (Hannover, DE)

Presentation thumbnail

Digoxin lowers pulmonary artery pressures and heart rate in patients with heart failure and reduced ejection fraction

Professor J. Lindenfeld (Nashville, US)

Presentation thumbnail

Increased perirenal adipose tissue thickness is associated with autonomic dysfunction and reduced CGRP in patients with HFpEF: a prospective observational study

Doctor O. Polat (Afyonkarahisar, TR)

Presentation thumbnail

Impact of M-TEER on health status in patients with moderate-to-severe functional mitral regurgitation and heart failure: results from RESHAPE-HF2

Professor J. Butler (Dallas, US)

Access the full session

Session thumbnail

Registries and clinical trials: new onset and chronic heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025

You may be interested in

Congress Session

Breaking the barriers in guideline-directed medical therapy implementation in heart failure

Congress Presentation

Audience Q&A

Congress Presentation

Gaps between guidelines and everyday clinical practice in the treatment of heart failure patients with reduced ejection fraction (HFrEF): we still have much to learn

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources